WuXi AppTec

Company Overview

WuXi AppTec is a global research, development, and manufacturing partner based in Shanghai, China. It operates an integrated platform that supports pharmaceutical, biotech, and chemical organizations, moving from early discovery through development and into manufacturing. Its capabilities cover a wide range of work, from small-molecule discovery chemistry and biology to DMPK, safety testing, clinical research, and large-scale production, allowing teams to keep projects moving within a single, connected ecosystem.

Wuxi AppTec’s in vitro ADME services help researchers gain a clearer picture of how a compound is absorbed, metabolized, and whether it may interact with other pathways in ways that could raise safety concerns. It offers bioanalytical and biomarker measurement capabilities that feed directly into preclinical toxicology work. It also facilitates the identification of early signs of cellular stress, genotoxicity, and organ-specific effects before they escalate into more severe issues.

WuXi AppTec operates through an integrated development platform that provides clients with a single development framework for conducting in vitro toxicology, DMPK, safety pharmacology, and preclinical bioanalysis, enabling a seamless transition of its drug development programs into the required regulatory studies.

Financial Highlights (FY 2025)

Company's Business Segments

• WuXi Chemistry : It deals with the chemistry business of the company.
• WuXi Testing : It deals with the testing business of the company.
• WuXi Biology : It deals with the biology business of the company.
• Discontinued Operations : WuXi ATU and WuXi DDSU